Say it is ‘so’
A new study finds that a drug previously approved by the FDA to treat Type 2 diabetes is helping people, without diabetes, drop major weight. Researchers stated the amount of pounds dropped in some people, was on par or greater than that achieved by a gastric bypass operation.
It requires a weekly dose of the medication Tizepatide, which is sold under the brand name Mounjaro. The drug was recently approved and tested at three doses.
Study participants who were overweight or obese and took 5mg of the drug lost an average of 35 pounds. People on the highest dose, 15mg, lost on average 52 pounds.
Typical weight loss through surgery to is 49 pounds, making the new drug more efficient without requiring a patient to go under the knife.
Declaring that the once-weekly injections proved “substantial and sustained reductions in body weight,” researchers with the New England Journal of Medicine touted their findings.
More than 2,500 adults with a BMI between 27 and 30 or more and at least one weight-related health complication took part in a phase 3 double-blind random drug trial. None of the participants had diabetes. The study involved different doses, as well as a placebo.
In addition to the weekly shot, they received lifestyle interventions counseling sessions aimed at healthy eating and diet.
After sticking with the protocol for almost a year and a half, 9 out of 10 people in the study saw significant weight loss.
More than 40% of Americans fall into the obese category according to the Centers for Disease Control and Prevention (CDC). Being overweight is a major risk factor for nearly all the nation’s top killers; including cardiovascular disease and cancer.
The Food and Drug Administration approved the drug to help fight diabetes last month. It is not yet approved for obesity.